<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274856</url>
  </required_header>
  <id_info>
    <org_study_id>GLWL-PWS</org_study_id>
    <nct_id>NCT03274856</nct_id>
  </id_info>
  <brief_title>A Study of GLWL-01 in Patients With Prader-Willi Syndrome</brief_title>
  <official_title>A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GLWL Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GLWL Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the
      treatment of patients with Prader-Willi Syndrome (PWS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be assigned to one of two treatment sequences (GLWL-01/Placebo or
      Placebo/GLWL-01), with each sequence consisting of two treatment periods separated by a
      washout period
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">September 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment total score on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT)</measure>
    <time_frame>Up to approximately 6 weeks</time_frame>
    <description>GLWL-01 compared with placebo on the post-treatment HQ-CT score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs</measure>
    <time_frame>Baseline up to approximately 18 weeks</time_frame>
    <description>Evaluate the safety and tolerability of GLWL-01</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Global Impression of Change (CGIC)</measure>
    <time_frame>Baseline up to approximately 6 weeks</time_frame>
    <description>GLWL-01 compared with placebo in the CGIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time zero to 12 hours (AUC0-12)</measure>
    <time_frame>Baseline up to approximately 6 weeks</time_frame>
    <description>Pharmacokinetics after single and multiple oral dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Baseline up to approximately 6 weeks</time_frame>
    <description>Pharmacokinetics after single and multiple oral dosing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GLWL-01 (450mg) twice a day/ Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo / GLWL-01 (450mg), twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01</intervention_name>
    <description>Oral administration of 3 capsules, twice a day</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of 3 capsules, twice a day</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of PWS based on genetic confirmation using DNA method

          -  Body mass index (BMI) of 27 to 60 kg/m2

          -  No evidence of weight excursion beyond 10% of baseline weight

          -  Patients must provide assent and have a reliable caregiver (must have been caring for
             the patient for at least 6 months) who provides a separate written informed consent to
             participate. The caregiver is expected to be the primary caregiver throughout the
             study and must be in frequent contact with the patient (defined as at least 4 awake
             hours per day). The caregiver must be able to communicate with site personnel and in
             the investigator's opinion must have adequate literacy to complete questionnaires. If
             a caregiver cannot continue, 1 caregiver replacement is allowed

          -  Are on a stable diet and exercise regimen for &gt;2 months prior

        Exclusion Criteria:

          -  Current enrollment in or discontinuation within the last 30 days from a clinical trial
             involving any investigational drug or device

          -  Are currently living in a group home for more than 50% of the time

          -  A history or presence of other medical illness that indicates a medical problem that
             would preclude study participation

          -  Have an estimated glomerular filtration rate &lt;60 mL/minute/1.73 m2. Have
             macroalbuminuria (defined as spot urine albumin to creatinine ratio of &gt;300 μg/mg) or
             hematuria

          -  Are hypertensive (defined as sitting systolic blood pressure (BP) greater than or
             equal to (≥)140 millimeters of mercury (mmHg) and diastolic BP ≥90 mmHg)

          -  Patients on weight loss medications within 30 days of dosing, or with a history of
             bariatric surgery

          -  Unable to refrain from or anticipates the use of:

               1. Any drugs known to be significant inhibitors of cytochrome P450 (CYP)3A enzymes
                  and/or P-glycoprotein (P-gp) including regular consumption of grapefruit or
                  grapefruit juice for 14 days prior to the first dose. Acetaminophen (up to 2
                  grams per 24-hour period) may be permitted

               2. Any drugs known to be significant inducers of CYP3A enzymes and/or P-gp,
                  including St. John's Wort

               3. Any medications that prolong the QT interval/corrected QT interval (QTc)

          -  Currently taking simvastatin &gt;10 mg per day, atorvastatin &gt;20 mg per day, or
             lovastatin &gt;20 mg per day, or have a history of statin-induced myopathy/rhabdomyolysis

          -  Unsuitable for inclusion in the study in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>GLWL Research Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>317-651-7036</phone>
    <email>GLWL@Choruspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Winograd</last_name>
      <phone>858-966-8453</phone>
      <email>rwinograd@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Bird</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Giordano</last_name>
      <phone>352-294-5280</phone>
      <email>bgiordano@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals, Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Lynn</last_name>
      <phone>216-844-7124</phone>
      <email>audrey.lynn@Uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Naveen Uli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Black</last_name>
      <phone>615-343-5846</phone>
      <email>margo.black@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Diabetes Institute, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristie Dehaan</last_name>
      <phone>780-492-1098</phone>
      <email>dehaan@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrea Haqq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Bordeleau</last_name>
      <phone>514-890-8000</phone>
      <email>andre.lacroix@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Lacroix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ste-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Champagne</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>6788</phone_ext>
      <email>caroline.champagne@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Cheri Deal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

